Exhibit 99.1 CENCORA REPORTS FISCAL 2025 FOURTH QUARTER AND FISCAL YEAR END RESULTS "Cencora furthered key initiatives in fiscal 2025 to fortify our leading position in healthcare, most notably by enhancing our position in specialty through our acquisition of RCA as well as the decision to strategically refocus our existing business portfolio," said Bob Mauch, President and Chief Executive Officer of Cencora. "Our strategic drivers of prioritizing growth-oriented investments, accelerating digital transforma ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September quarter of fiscal 2025, compared to $0.02 in the prior year quarter. Adjusted diluted EPS, which is a. ...

FRANKLIN LAKES, N.J., Nov. 3, 2025 /PRNewswire/ --Â BD (Becton, Dickinson and Company) (NYSE: BDX)Â a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Conformité Européenne (CE) marking in the European Union for its Enteric Bacterial Panel* (EBP) and Enteric Bacterial Panel plus* (EBP plus) for the BD CORâ"¢ System. Continue Reading BD Receives FDA 510(k) Clearance and CE-IVDR Certification for High-Throughput Enteric Bac ...

Core Insights - Cencora (COR) is expected to report quarterly earnings of $3.79 per share, reflecting a year-over-year increase of 13.5% [1] - Projected revenues for the quarter are anticipated to be $83.16 billion, which represents a 5.2% increase from the previous year [1] - The consensus EPS estimate has been adjusted upward by 0.3% over the past 30 days, indicating a reassessment by analysts [1] Revenue Projections - Analysts project 'Revenue- Total International Healthcare Solutions' to reach $8.00 billion, indicating an 8.3% increase from the prior-year quarter [4] - The consensus for 'Revenue- Total U.S. Healthcare Solutions' is $75.11 billion, reflecting a year-over-year change of 4.8% [4] - 'Revenue- International Healthcare Solutions- Alliance Healthcare' is expected to be $6.47 billion, showing an 8.9% year-over-year increase [5] - 'Revenue- U.S. Healthcare Solutions- Animal Health' is estimated at $1.36 billion, suggesting a decline of 3.1% year over year [5] - The estimate for 'Revenue- U.S. Healthcare Solutions- Human Health' stands at $73.80 billion, indicating a 5% increase from the previous year [5] - 'Revenue- International Healthcare Solutions- Other Healthcare Solutions' is forecasted to reach $1.61 billion, reflecting an 11.7% increase [6] Operating Income Estimates - 'Operating income- Non-GAAP- International Healthcare Solutions' is projected to be $170.29 million, compared to $153.67 million from the previous year [6] - 'Operating income- Non-GAAP- U.S. Healthcare Solutions' is expected to arrive at $840.57 million, up from $697.38 million year-over-year [7] Stock Performance - Cencora shares have increased by 10.6% over the past month, outperforming the Zacks S&P 500 composite, which rose by 2.1% [7] - Cencora holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [7]

Core Insights - Cencora, Inc. is a leading global healthcare solutions provider with a market cap of $63.8 billion, focusing on sourcing and distributing pharmaceutical and healthcare products while offering logistics, data analytics, and commercialization services [1] Financial Performance - Cencora is expected to announce its fiscal Q4 2025 results on November 5, with analysts forecasting an adjusted EPS of $3.79, representing a 13.5% increase from $3.34 in the same quarter last year [2] - For fiscal 2025, the projected adjusted EPS is $15.93, reflecting a 15.8% increase from $13.76 in fiscal 2024 [3] Stock Performance - Cencora's shares have increased by over 39% in the past 52 weeks, outperforming the S&P 500 Index's rise of 15.1% and the Health Care Select Sector SPDR Fund's decline of 4.1% during the same period [4] Recent Results and Challenges - In Q3 2025, Cencora reported an adjusted EPS of $4 and revenue of $80.66 billion, but shares fell by 2.9% due to a 12.9% decline in operating income from the International Healthcare Solutions segment, increased interest expenses of $81.8 million (up $50.5 million), and a 17.3% rise in operating expenses [5] Analyst Ratings - The consensus rating for Cencora's stock is bullish, with a "Strong Buy" rating from 11 out of 15 analysts, while four analysts recommend a "Hold" rating. The average price target is $339.71, indicating a potential upside of 3.3% from current levels [6]

Core Insights - Cencora, Inc. is a significant player in the pharmaceutical distribution industry, with a market capitalization of $58.7 billion, providing a range of healthcare products and services [1][2] Company Overview - Cencora offers end-to-end pharmaceutical commercialization solutions, over-the-counter healthcare products, home healthcare supplies, and related services to healthcare providers [1] - The company is categorized as a large-cap stock due to its market cap exceeding $10 billion, highlighting its size and influence in the medical distribution sector [2] Financial Performance - In Q3, Cencora reported revenue of $80.7 billion, an increase of 8.7% year-over-year, and adjusted EPS rose by 19.8% to $4 [5] - The company has raised its fiscal 2025 adjusted EPS guidance to a range of $15.85 to $16 [5] Stock Performance - Cencora's stock has seen a year-to-date increase of 34.6% and a 27.3% rise over the past 52 weeks, outperforming the Health Care Select Sector SPDR Fund's marginal gains [4] - Despite a recent drop of 2.2% from its 52-week high of $309.35, the stock has gained 2.5% over the past three months, outperforming the XLV's 1% gain [3][4] Strategic Positioning - The company's strengths include its strategic positioning in the healthcare value chain, a diversified portfolio, and scale-driven bargaining power [2] - Cencora leverages technological capabilities in supply chain management and data analytics to achieve high operational efficiency, with fill rates exceeding 99% [2]

Group 1 - Cencora is participating in the Morgan Stanley Healthcare Conference, indicating its engagement with investors and the healthcare community [2] - The company is represented by key executives, including Jim Cleary, EVP and CFO, and Bennett Murphy, SVP of IR and Enterprise Productivity, highlighting its leadership presence [2]

Summary of Cencora (NYSE:COR) FY Conference Call - September 10, 2025 Company Overview - **Company**: Cencora (NYSE:COR) - **Event**: FY Conference Call - **Date**: September 10, 2025 Key Industry Insights - **Healthcare Services**: The discussion primarily revolves around the healthcare services industry, focusing on Cencora's performance and strategic initiatives. Core Financial Performance - **EPS Guidance**: Cencora raised its fiscal year 2025 EPS guidance five times since November, now implying a growth of 14% to 15% [3][5] - **Operating Income Growth**: The adjusted operating income guidance for fiscal year 2025 is set at 15% to 16%, with the U.S. segment expected to grow by 20% to 21% [5][6] - **Long-term Growth Goals**: The company maintains a long-term guidance of 8% to 12% EPS growth, with organic operating income growth projected at 5% to 8% [11][10] Strategic Acquisitions and Market Position - **RCA Acquisition**: The RCA acquisition is highlighted as a significant tailwind for fiscal year 2026, contributing positively to growth [8][9] - **Oncology Customer Loss**: A headwind is anticipated due to the loss of an oncology customer following its acquisition by a competitor [9] - **Specialty Business**: Cencora's specialty business is performing strongly, particularly in physician practices and health systems, with a focus on high-value services [25][26] Market Dynamics - **Utilization Trends**: Strong utilization trends are noted, especially in specialty products, which are expected to continue [14][6] - **Drug Pricing Environment**: The generic drug pricing environment shows moderation in deflation, while branded pricing remains in line with expectations [16][17] Partnerships and Collaborations - **Cigna and Walgreens**: Cencora maintains strong partnerships with Cigna and Walgreens, with contracts extending through 2029 and 2031, respectively [46][47] - **Biosimilars**: The company sees biosimilars as a continuing tailwind for its specialty business, particularly in oncology and retina [41] International Business and Growth - **International Segment Performance**: The international segment has faced challenges, particularly in specialty logistics and consulting services, but is expected to stabilize [63][64] - **World Courier**: Cencora's World Courier business, a leader in clinical trial logistics, is anticipated to recover as market conditions improve [66] Regulatory Environment - **Regulatory Dynamics**: The company is closely monitoring potential regulatory changes, including pharma tariffs and drug pricing reforms, to mitigate risks [50][51] Investment and Capital Deployment - **Capital Deployment Strategy**: Cencora emphasizes balanced capital deployment, focusing on growth-oriented investments and strategic acquisitions [71][72] - **Digital Transformation**: The company is investing in digital transformation to enhance operational efficiency, particularly in finance and internal audits [75][76] Conclusion Cencora is positioned for continued growth through strategic acquisitions, strong performance in its U.S. segment, and a focus on specialty products. The company is navigating challenges in the international market while maintaining robust partnerships and monitoring regulatory changes.

Group 1 - The presence of Jim Cleary, EVP and CFO, and Bennett Murphy, EVP of Enterprise productivity, indicates a focus on leadership and strategic direction within the company [1] - Eric Coldwell, a senior research analyst, expresses a long-standing positive view on Cencora, highlighting the company's strong performance in the pharma services and outsourcing logistics sectors [2][4] - The company has been recognized as one of the best investment ideas over the past five years, particularly in the distribution and lab subsectors, with distributors showing exceptional performance [4]

Summary of Conference Call Company Overview - The conference call involved Cencora, a company in the pharmaceutical services and related outsourcing industry, with a focus on distribution and logistics [1][3]. Key Points and Arguments 1. **Strong Performance and Growth Guidance** - Cencora reported an operating income growth guidance of 15-16% for the fiscal year, with the U.S. segment expected to grow by 20-21% [6][7]. - The company exceeded expectations due to strong utilization trends and growth in specialty product sales [7]. 2. **Acquisition Impact** - The RCA acquisition contributed positively to the growth, providing a tailwind for the first quarter [7][10]. - The acquisition was described as highly accretive and aligned with Cencora's existing business model [10][12]. 3. **Long-term Growth Strategy** - Cencora maintains a long-term guidance of 5-8% organic operating income growth, with an additional 3-4% from capital deployment, and earnings per share growth of 8-12% [8]. - The company is focused on growth-oriented investments, particularly in MSOs (Managed Service Organizations) and infrastructure [30]. 4. **Challenges in International Segment** - The International Healthcare Solutions segment, which accounts for 15% of operating income, has underperformed due to a subdued clinical trials market affecting World Courier and PharmaLex [33][34]. - There are signs of improvement in the clinical trials market, and the company is planning for stabilization in this segment [34]. 5. **Regulatory Compliance and Supply Chain Security** - Cencora has been preparing for the Drug Supply Chain Security Act (DSCSA) and views it as an opportunity to enhance their value proposition in the pharmaceutical supply chain [15][16]. - The company believes that the DSCSA will create additional opportunities due to the data captured during compliance [17]. 6. **Market Position in Ophthalmology** - Cencora has a strong position in the ophthalmology market, particularly in the retina space, and is leveraging its MSO strategy to enhance service offerings [11][44]. - The company is focused on providing higher value services and has seen strong performance in clinical trial sites related to retina practices [12]. 7. **Independent Pharmacy Support** - Cencora supports independent pharmacies through value-added services, which have helped them maintain market share despite challenges faced by larger chains [48][53]. - The company has been recognized for its customer satisfaction and continues to grow its independent pharmacy network [49]. 8. **Capital Deployment Strategy** - Cencora is expected to generate between $15 billion and $20 billion in free cash flow by the end of the decade, with plans for strategic acquisitions, capital expenditures, and opportunistic share repurchases [66]. - The company has been growing its dividend at 8% in the most recent year, indicating a commitment to returning value to shareholders [66]. Additional Important Insights - The company is focused on digital transformation, productivity, and talent development as part of its strategic drivers [30]. - Cencora's leadership emphasizes the importance of maintaining a pharmaceutical-centric approach across all business segments [44]. - The management team expressed confidence in their long-term growth strategy despite current market challenges [8][34].